Table 2.
Meta-Analyses of Randomized Controlled Trials of Vasoactive Drugs for Reversal of HRS
| Meta- Analysis Studies |
Number of Studies |
Drug Combinations | Odds Ratio (OR) or Risk Ratio (RR) for HRS Reversal (95% Confidence Interval) |
Heterogeneity (I2) |
Test for Overall Effect (P Value) |
Studies Included in the Meta-Analysis |
|---|---|---|---|---|---|---|
| Fabrizi (2009)96 | 5 | Terlipressin vs. placebo | OR=8.09 [3.52, 18.59] | 41% | 0.0001 | Hadengue (1998)106, Solanki (2003)112, Sanyal (2008)109, Martin-Llahi (2008)107, Neri (2008)108 |
| Gluud (2010)99 | 4 | Terlipressin alone or with albumin vs. no intervention or albumin | RR=3.76 [2.21, 6.39] | 0% | Not reported | Solanki (2003)112, Sanyal (2008)109, Martin-Llahi (2008)107, Neri (2008)108 |
| Sagi (2010)102 | 4 | Terlipressin vs. placebo | RR=3.66 [2.15, 6.23] | 0% | <0.00001 | Solanki (2003)112, Sanyal (2008)109, Martin-Llahi (2008)107, Neri (2008)108 |
| Dobre (2011)95 | 4 | Terlipressin vs. placebo | OR=7.47 [3.17, 17.59] | 24% | <0.00001 | Solanki (2003)112, Sanyal (2008)109, Martin-Llahi (2008)107, Neri (2008)108 |
| 2 | Terlipressin vs. noradrenaline | OR=1.23 [0.43, 3.54] | 0% | 0.70 | Alessandria (2007)103,Sharma (2008)110 | |
| 6 | Terlipressin vs. placebo/terlipressin vs. noradrenaline | OR=4.49 [1.75, 11.56] | 56% | 0.002 | Solanki (2003)112, Sanyal (2008)109, Martin-Llahi (2008)107, Neri (2008)108, Alessandria (2007)103, Sharma (2008)110 | |
| Gluud (2012)100 | 4 | Terlipressin alone or with albumin vs. no intervention or albumin | RR=3.76 [2.21, 6.39] | 0% | <0.00001 | Solanki (2003)112, Sanyal (2008)109, Martin-Llahi (2008)107, Neri (2008)108 |
| Mattos (2016)101 | 4 | Terlipressin vs. noradrenaline | RR=1.03 [0.81, 1.31] | 0% | 0.80 | Alessandria (2007)103, Sharma (2008)110, Singh (2012)111, Ghosh (2013)105 |
| Gifford (2017)98 | 5 | Terlipressin+/-albumin vs. no intervention/placebo+/-albumin | RR=2.54 [1.51, 4.26] | 52% | 0.0004 | Solanki (2003)112, Sanyal (2008)109, Martin-Llahi (2008)107, Neri (2008)108, Boyer (2016)117 |
| 1 | Terlipressin infusion vs. terlipressin bolus | RR=1.22 [0.77, 1.93] | Not applicable | 0.40 | Cavallin (2016)92 | |
| 3 | Terlipressin vs. noradrenaline | RR=0.99 [0.67, 1.45] | 0% | 0.94 | Alessandria (2007)103, Sharma (2008)110, Singh (2012)111 | |
| 1 | Terlipressin+albumin vs. dopamine+standard care | RR=2.00 [1.14, 3.52] | Not applicable | 0.02 | Silawat (2011)114 | |
| 1 | Noradrenaline+albumin vs. octreotide+midodrine+albumin | RR=1.25 [0.70, 2.24] | Not applicable | 0.45 | Tavakkoli (2012)113 | |
| Facciorusso (2017)97 | 5 | Terlipressin vs. placebo | OR=4.48 [1.88, 10.67] | 60% | 0.0007 | Sanyal (2008)109, Martin- Llahi (2008)107, Neri (2008)108, Zafar (2012)116, Boyer (2016)117 |
| 4 | Terlipressin vs. noradrenaline | OR=0.89 [0.47, 1.69] | 0% | 0.72 | Alessandria (2007)103, Sharma (2008)110, Singh (2012)111, Indrabi (2013)115 | |
| 1 | Terlipressin vs. octreotide+midodrine | OR=26.25 [3.07, 224.21] | Not applicable | 0.003 | Cavallin (2015)104 | |
| 1 | Noradrenaline vs. octreotide+midodrine | OR=2.50 [0.19, 32.19] | Not applicable | 0.48 | Tavakkoli (2012)113 |